Notice of primary insider trading
Member of the Board Anders Bade's new direct holding in Navamedic after the purchase is 27,750 shares. His 2,000 new shares were purchased at NOK 13,80 per share. In addition, Mr. Bade has an ownership position in Krabad AS, which holds 40,000 Navamedic shares.
Advance Invest and Consulting's new holding in Navamedic after the purchase is 488,060 shares. The 2,500 new shares were purchased at an average of NOK 14,42 per share.
CFO Jon W. Ringvold's new direct holding in Navamedic after the purchase is 14,000 shares. His 1,500 new shares were purchased at NOK 14,40 per share. In addition, Mr. Ringvold controls 46,000 shares in Navamedic through his ownership in Wiwil AS.
For further information, please contact:
Jon W. Ringvold, CFO/IR
E-mail: jon.ringvold@navamedic.com
Office: +47 67 11 25 44
Mobile: +47 99 15 85 34
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company`s products will be sold through a network of sales, marketing and distribution partners. Navamedic`s product Glucomed has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.